Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia · 2008
Narrowband UVB phototherapy in vitiligo: evaluation of results in 53 patients.
Клиническое исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Percivalle S, Piccino R, Caccialanza M, Forti S
Аннотация
AIM: Narrowband UVB (NBUVB)phototherapy has been used for vitiligo for years, but today there are no standardized protocols of treatment and follow-up data. A long-term study on 53 patients with localized or diffuse vitiligo is presented with the aim at improving the data availability in the literature.
METHODS: Phototherapy was administered two times a week on non-consecutive days; the treatment was continued for one year. The mean total dose administered was 201.28 J/cm2.The response to phototherapy was expressed as percentage of repigmentation: a repigmentation greater than 75% was considered excellent, a repigmentation between 74% and 50% good, a repigmentation between 49% and 25% moderate, a repigmentation less than 24% mild. In case of absence of repigmentation, the patient was judged as non-responder
RESULTS: Three point eight percent of patients showed excellent response, 32.05% good response, 32.05% moderate response, 28.3% mild response, while the remaining 3.8% was not responsive. According to statistical analysis best responses, were observed in non-acral areas (P<0.001), in patients with recent vitiligo (P=0.003), in patients with negative family history for vitiligo (P=0.038), and in those not exposed to previous therapies (P=0.005). In 36 patients a mean follow-up of 19.78 months was obtained.
CONCLUSION: NBUVB phototherapy is useful and safe for vitiligo, but in the future it will be necessary to compare results of different studies using the same treatment protocols and to obtain data of series endowed with an adequate follow-up.
METHODS: Phototherapy was administered two times a week on non-consecutive days; the treatment was continued for one year. The mean total dose administered was 201.28 J/cm2.The response to phototherapy was expressed as percentage of repigmentation: a repigmentation greater than 75% was considered excellent, a repigmentation between 74% and 50% good, a repigmentation between 49% and 25% moderate, a repigmentation less than 24% mild. In case of absence of repigmentation, the patient was judged as non-responder
RESULTS: Three point eight percent of patients showed excellent response, 32.05% good response, 32.05% moderate response, 28.3% mild response, while the remaining 3.8% was not responsive. According to statistical analysis best responses, were observed in non-acral areas (P<0.001), in patients with recent vitiligo (P=0.003), in patients with negative family history for vitiligo (P=0.038), and in those not exposed to previous therapies (P=0.005). In 36 patients a mean follow-up of 19.78 months was obtained.
CONCLUSION: NBUVB phototherapy is useful and safe for vitiligo, but in the future it will be necessary to compare results of different studies using the same treatment protocols and to obtain data of series endowed with an adequate follow-up.